Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | MC4R | P32245 | 3/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27309933 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| SCHEMBL31469959 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| SCHEMBL4434645 | 0.91 | ALDH1A1 (0.70) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| SCHEMBL2444405 | 0.91 | ALDH1A1 (0.70) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| SCHEMBL526330 | 0.91 | ALDH1A1 (0.73) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| Hydrochloric Acid SCHEMBL3932337 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| SCHEMBL1792830 | 0.89 | MC4R (0.75) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| SCHEMBL22163700 | 0.88 | HTR2C (0.65) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| SCHEMBL22163701 | 0.87 | HTR2C (0.67) | ALDH1A1MC4RUSP2HPGDHTR2C | |
| SCHEMBL25156474 | 0.85 | HTR2C (0.58) | ALDH1A1MC4RUSP2HPGDHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| WO-2021112933-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-1723150-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005070941-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-1390034-A4 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1399160-A4 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO INC (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1399160-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | Merck & Co., Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1390034-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1379520-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | ALDH1A1 315/4885MC4R 557/4885USP2 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.